Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linagliptin + Pioglitazone Initial Combination in T2D
NCT00641043Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2008
- Primary completion
- Jun 2009
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing BI 1356 (5 mg) with Placebo matching BI 1356 5 mg (2 arms). Primary endpoint: HbA1c Change From Baseline at 24 weeks. Started Mar 2008; status: completed.
02
Drugs
linagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00641043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00641043.